Literature DB >> 1379313

BCR/ABL confers growth factor independence upon a murine myeloid cell line.

R A Mandanas1, H S Boswell, L Lu, D Leibowitz.   

Abstract

The BCR/ABL oncogene in chronic myelogenous leukemia produces an activated tyrosine kinase fusion protein (p210). Like other tyrosine kinase oncogenes, BCR/ABL can abrogate the interleukin-3 (IL-3) dependence of lymphoid cell lines. To investigate the ability of BCR/ABL to generate growth factor independence in myeloid cells, the IL-3 dependent myeloid cell line NFS/N1.H7 (H7) was transfected with the p210BCR/ABL-containing plasmid, pGD210. Stable clones A54 and A74 were capable of IL-3 independent growth and tumor formation in syngeneic mice. Relief of growth factor dependence was not mediated by autocrine release of IL-3. The baseline proliferation rate of the BCR/ABL transformed cells was greater than that of the parental H7 cells maximally stimulated by IL-3. Abundant constitutive expression of c-myc, c-jun, and c-fos was observed in the p210BCR/ABL transfectants even in low serum conditions. In contrast, c-myc expression in H7 cells was dependent upon IL-3 stimulation, and neither c-jun nor c-fos was highly expressed following IL-3 stimulation in H7 cells. Thus, BCR/ABL transformation and relief of IL-3 dependence involve not only pathways that can substitute for IL-3 induced growth via tyrosine kinase mediated signals, but also pathways that recruit constitutive c-jun and c-fos expression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379313

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

Authors:  T Skorski; A Bellacosa; M Nieborowska-Skorska; M Majewski; R Martinez; J K Choi; R Trotta; P Wlodarski; D Perrotti; T O Chan; M A Wasik; P N Tsichlis; B Calabretta
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

2.  Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen.

Authors:  Els Lierman; Helen Van Miegroet; Els Beullens; Jan Cools
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

3.  Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.

Authors:  Ryoko Kuribara; Hiroaki Honda; Hirotaka Matsui; Tetsuharu Shinjyo; Takeshi Inukai; Kanji Sugita; Shinpei Nakazawa; Hisamaru Hirai; Keiya Ozawa; Toshiya Inaba
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

4.  A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis.

Authors:  Qinghuang Chen; Ke Chen; Guijie Guo; Fang Li; Chao Chen; Song Wang; Grzegorz Nalepa; Shile Huang; Ji-Long Chen
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

Review 5.  The haemopoietic stem cell: between apoptosis and self renewal.

Authors:  Faris Q Alenzi; Badi Q Alenazi; Shamweel Y Ahmad; Mohamed L Salem; Ali A Al-Jabri; Richard K H Wyse
Journal:  Yale J Biol Med       Date:  2009-03

6.  Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway.

Authors:  T Tauchi; H S Boswell; D Leibowitz; H E Broxmeyer
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

7.  Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.

Authors:  E Deutsch; L Maggiorella; B Wen; M L Bonnet; K Khanfir; V Frascogna; A G Turhan; J Bourhis
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

8.  Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Authors:  Trever G Bivona; Collin M Blakely; Julia K Rotow; Philippe Gui; Wei Wu; Victoria M Raymond; Richard B Lanman; Frederic J Kaye; Nir Peled; Ferran Fece de la Cruz; Brandon Nadres; Ryan B Corcoran; Iwei Yeh; Boris C Bastian; Petr Starostik; Kimberly Newsom; Victor R Olivas; Alexander M Wolff; James S Fraser; Eric A Collisson; Caroline E McCoach; D Ross Camidge; Jose Pacheco; Lyudmila Bazhenova; Tianhong Li
Journal:  Clin Cancer Res       Date:  2019-09-23       Impact factor: 12.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.